Navigation Links
Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
Date:3/11/2008

SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer, today announced that an abstract detailing results from the RAV12 Phase 1/2a trial has been accepted as a poster discussion presentation at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO). The presentation is scheduled for May 30, 2008. Dr. Nancy Lewis of the Fox Chase Cancer Center is the abstract's first author and will make the presentation on behalf of the study's participating investigators.

The study, which enrolled 53 patients with adenocarcinomas bearing the RAAG12 antigen, particularly those of gastrointestinal (GI) origin, was conducted at 5 institutions in the US, the Sarah Cannon Cancer Center in Nashville, TN; the Fox Chase Cancer Center in Philadelphia, PA; Premiere Oncology in Santa Monica, CA; the University of Miami Medical Center in Miami, FL; and the Georgetown University Medical Center in Washington, DC.

About GI Cancers

Adenocarcinomas are malignant tumors of the epithelial cells that line glands or viscera. They typically spread by way of the circulatory or lymphatic systems and are poorly treated after metastatic dissemination. More than 90 percent of colon, stomach and pancreatic tumor specimens express the RAV12-defined antigen, RAAG12. Adenocarcinomas arising elsewhere, such as breast, endometrial, ovarian, lung and prostate, display the antigen at lower frequency.

About RAV12

RAV12 is a novel, chimeric monoclonal antibody that is directed against a primate-specific glycotope (sugar structure) that is widely displayed on the surfaces of tumor cells, particularly those of gastrointestinal origin (gastroesophageal, pancreatic, and colorectal cancers). Preclinical studies have demonstrated that RAV12 may kill tumor cells in a number of ways: first, the antibody is directly cytotoxic to a human colon cancer cell line in vitro through induction of oncotic cell death, a form of cell death characterized by cell and organelle swelling and loss of membrane integrity; second, the antibody mediates antibody-dependent cellular cytotoxicity; third, the antibody mediates complement dependent cell killing; and finally, the antibody alters cellular signaling required for cell survival. RAV12 is highly efficacious in human colon, gastric, and pancreatic tumor xenograft models in vivo and has been found to be well tolerated in repeat dose primate toxicology studies.

About Raven

Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery process simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for optimizing the production of MAbs targeting cell-surface proteins, including the use of human tissue-specific progenitor and tumor stem cell lines developed at Raven.

To date Raven has identified multiple candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer.

On November 12, 2007, Raven and VaxGen Inc. (Pink Sheets: VXGN.PK), a biopharmaceutical company, announced that their respective boards of directors unanimously approved a definitive merger agreement. The merger is expected to create a drug development company with a robust pipeline of monoclonal antibody candidates in oncology, proprietary antibody discovery platforms, biopharmaceutical manufacturing capabilities and sufficient cash to fund operations at least through the end of 2009. The merger is expected to close in the first half of 2008.


'/>"/>
SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
2. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
3. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
4. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
5. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
8. Cynosure Announces Upcoming Investor Presentations at Cowen and Citi Investor Conferences
9. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
10. Mentice AB Announces Leadership Changes Within Its Worldwide Operations
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , December 2, 2016 The immunohistochemistry ... growing at a CAGR of 7.3% during the forecast period of ... and diagnostic laboratories segment accounted for the largest share of immunohistochemistry ... ... on global immunohistochemistry (IHC) market spread across 225 pages, profiling 10 ...
(Date:11/30/2016)... 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... excited to announce the formation of EyGen, Ltd. ... ophthalmology assets through proof of concept. EyGen,s lead ... Portage Pharmaceuticals Limited and being developed for topical ... anterior segment diseases. This agent has the potential ...
(Date:11/30/2016)... DIEGO and BEIJING , ... a leading commercial provider of genomic services and solutions ... announced today that it has completed a USD $75 ... Merchants Bank Co., Ltd.,s CMB International Capital Management ( ... Innovation Investment Management Co., Ltd. ("SDIC Innovation") and Shanghai ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... advanced technology applications, introduces the 5th generation, ultra-bright, Laser-Driven Light Source, the EQ-77, ... Light Source (LDLS™) technology, the EQ-77 offers higher radiance and irradiance from a ...
Breaking Biology Technology:
(Date:11/19/2016)... Securus Technologies, a leading provider of civil and criminal ... monitoring, announced today that it has offered a challenge ... technology judge determine who has the largest and best ... platform, and the best customer service. "ICSolutions ... we do – which clearly is not the case ...
(Date:11/15/2016)... 2016 Research and Markets has announced the ... report to their offering. ... The ... 2021 from USD 6.21 Billion in 2016, growing at a CAGR ... the bioinformatics market is driven by the growing demand for nucleic ...
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
Breaking Biology News(10 mins):